A Clinical Study to Test Long Term Safety of GLPG1690 for Patients With Systemic Sclerosis
Status:
Terminated
Trial end date:
2021-04-13
Target enrollment:
Participant gender:
Summary
This study is the extension of the double-blind study GLPG1690-CL-204 (NCT03798366). The main
purpose of the study is to see how GLPG1690 is tolerated in participants with systemic
sclerosis and whether there are any side effects in a long-term treatment period.